公开(公告)号：US20100120693A1

公开(公告)日：2010-05-13

申请号：US12691125

申请日：2010-01-21

申请人： Kenji OKAJIMA ,  Fujio Matsuo ,  Hiroyuki Sutoh ,  Yoichi Ogata ,  Tomohiro Nakagaki

发明人： Kenji OKAJIMA ,  Fujio Matsuo ,  Hiroyuki Sutoh ,  Yoichi Ogata ,  Tomohiro Nakagaki

IPC分类号： A61K38/16 ,  A61P35/00

CPC分类号： A61K38/4866

摘要： A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.

摘要翻译： 提供了一种用于改善恶性肿瘤治疗预后生存的药物，可以改善基底疾病是恶性肿瘤，特别是造血器官恶性肿瘤的DIC患者的预后生存。 根据本发明的药物包含作为主要活性成分的由血浆获得或通过使用遗传重组技术制备的活化蛋白C，并有效延长了基础疾病是恶性肿瘤，特别是恶性肿瘤的DIC患者的寿命 在造血器官。 特别地，药物可以减少化学治疗剂在恶性肿瘤化疗中的不良副作用，以增强所述治疗的疗效并改善恶性肿瘤患者的预后。